Can Fite Biopharma Ltd (NASDAQ:CANF) received a $6.00 target price from equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday. The firm presently has a “buy” rating on the stock.

Can Fite Biopharma (NASDAQ CANF) opened at 1.53 on Thursday. The company’s market cap is $23.72 million. Can Fite Biopharma has a 52-week low of $1.53 and a 52-week high of $2.82. The firm’s 50 day moving average is $1.77 and its 200 day moving average is $1.86.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with's FREE daily email newsletter.